Trending News

#Covid-19 #Immunology / Virology & Vaccines

Moderna vaccine protective against UK and South African variants

Moderna has released results from in vitro neutralisation studies of sera from individuals vaccinated with its COVID-19 vaccine showing activity against emerging strains of SARS-CoV-2. Vaccination with the Moderna COVID-19 vaccine produced neutralising titers against all key emerging variants tested, including B.1.1.7 and B.1.351, first identified in the UK and… Read More

#News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Novavax and Canadian government purchase agreement for COVID-19 vaccine

Novavax, the late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, has finalised an agreement with the government of Canada to supply up to 76 million doses of NVX-CoV2373, the company’s recombinant protein-based COVID-19 vaccine. Canada has committed to purchase 52 million doses of the vaccine with the option… Read More

#Covid-19 #News #Trending News

#AI / data analytics / healthtech / informatics #Drug discovery

NovAliX partners with Chemical.AI to develop artificial intelligence toolkit for drug discovery

NovAliX, a drug discovery-focused contract research organisation (CRO), and Chemical.AI, an artificial intelligence (AI) company leveraging human expertise and cutting-edge AI technology for chemistry and pharmaceuticals, have created a strategic It is hoped that the affiliation will help create the most relevant AI solutions for drug developers. NovAliX brings 20… Read More

#Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Swiss government authorises Moderna vaccine and secures 7.5 million doses

Swissmedic, the Swiss Agency for Therapeutic Products, has authorised the COVID-19 Moderna Vaccine in Switzerland. The authorisation is given according to the ordinary approvals procedure and is based on a rolling submission of data and the totality of scientific evidence shared by the company, including a data analysis from the… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Moderna vaccine becomes third COVID-19 to be approved by UK regulator

The COVID-19 vaccine developed by Moderna has been given regulatory approval for supply by the Medicines and Healthcare products Regulatory Agency (MHRA). This follows a thorough and rigorous assessment by the MHRA’s teams of scientists, including advice from the independent Commission on Human Medicines, which reviewed in depth all the… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Novavax seals agreement with Australia for 51 million doses of COVID-19 Vaccine

Novavax has executed an Advance Purchase Agreement with the Commonwealth of Australia for 51 million doses of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. This follows an agreement in principle that was announced in November 2020. NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

European Commission authorises Moderna COVID-19 vaccine in Europe

The European Commission has granted a conditional marketing authorisation (CMA) for Moderna’s COVID-19 vaccine Moderna, allowing vaccination programs using the Moderna vaccine to be rolled out across the European Union. The authorisation is based upon the recommendation of the European Medicines Agency (EMA) for use of the COVID-19 Vaccine Moderna… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

“A moment to celebrate British innovation”: Oxford AstraZeneca vaccine gets go-ahead

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has provided authorisation for emergency supply of the Oxford University AstraZeneca COVID-19 vaccine for the active immunisation of individuals 18 years or older. The authorisation recommends two doses administered with an interval of between four and 12 weeks. This regimen was shown… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

“A great day for British science”: MHRA approves Oxford COVID-19 vaccine

The UK government has accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK. The Joint Committee on Vaccination and Immunisation (JCVI) will also publish its latest advice for the priority groups to receive… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Antibody #Assay development optimisation & technology

LSBIO acquires Absolute Antibody

LSBio, a provider of antibodies and life science research reagents, has acquired UK-based Absolute Antibody, its sister company Kerafast. LSBio provides IHC-validated reagent antibodies and services to the global community of academic, pharmaceutical and biotech researchers. The company has built a catalogue of more than 750,000 reagent antibodies, assay kits,… Read More

#News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

COVID-19 vaccine: “That is how our country will begin to move forward,” says Fauci

The FDA has issued an Emergency Use Authorization (EUA) to Moderna, for its COVID-19 vaccine, which was co-developed with scientists at the NIH National Institute of Allergy and Infectious Diseases (NIAID) and Moderna. This partnership has enabled NIH and Moderna to develop a COVID-19 vaccine within a year that will… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Antibody #Covid-19 #Immunology / Virology & Vaccines #T-Cells

Oxford vaccine stimulates broad antibody and T cell functions

Researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing Phase III trials, and how ChAdOx1 nCov-19 is induces broad antibody and T cell functions. These findings… Read More

#Covid-19 #Editor's Choice #News #Trending News